Essential thrombocythemia vs. early/prefibrotic myelofibrosis: Why does it matter

Giovanni Barosi

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Essential thrombocythemia (ET) and primary myelofibrosis (PMF), together with polycythemia vera (PV) are Phildelphia-negative (Ph-neg) classical myeloproliferative neoplasms (MPN). ET has been traditionally identified by thrombocytosis and absence of relevant bone marrow (BM) fibrosis, while PMF by BM reticulin or collagen fibrosis with megakaryocyte hyperplasia and dysplasia, and extramedullary hematopoiesis. These diagnostic profiles have been challenged since 2001 when the World Health Organization (WHO) has included in the domain of PMF a new category of patients, namely early/prefibrotic MF, characterized by the absence of relevant reticulin fibrosis in BM, dual megakaryocyte and granulocyte proliferation, and megakaryocyte dysplasia. This review is focused on summarizing the diagnostic uncertainties of early/ prefibrotic myelofibrosis, recent advances in our understanding of the biology of the variant, and the accompanying translational implications.

Original languageEnglish
Pages (from-to)129-140
Number of pages12
JournalBest Practice and Research: Clinical Haematology
Volume27
Issue number2
DOIs
Publication statusPublished - 2014

Fingerprint

Essential Thrombocythemia
Primary Myelofibrosis
Reticulin
Bone
Megakaryocytes
Collagen
Health
Extramedullary Hematopoiesis
Thrombocytosis
Polycythemia Vera
Granulocytes
Uncertainty
Hyperplasia
Fibrosis
Bone Marrow
Neoplasms

Keywords

  • Bone marrow biopsy
  • Early/prefibrotic myelofibrosis
  • Essential throbocythemia
  • Primary myelofibrosis

ASJC Scopus subject areas

  • Oncology
  • Clinical Biochemistry
  • Medicine(all)

Cite this

Essential thrombocythemia vs. early/prefibrotic myelofibrosis : Why does it matter. / Barosi, Giovanni.

In: Best Practice and Research: Clinical Haematology, Vol. 27, No. 2, 2014, p. 129-140.

Research output: Contribution to journalArticle

@article{08afd966d6b047c89d94019229034e2a,
title = "Essential thrombocythemia vs. early/prefibrotic myelofibrosis: Why does it matter",
abstract = "Essential thrombocythemia (ET) and primary myelofibrosis (PMF), together with polycythemia vera (PV) are Phildelphia-negative (Ph-neg) classical myeloproliferative neoplasms (MPN). ET has been traditionally identified by thrombocytosis and absence of relevant bone marrow (BM) fibrosis, while PMF by BM reticulin or collagen fibrosis with megakaryocyte hyperplasia and dysplasia, and extramedullary hematopoiesis. These diagnostic profiles have been challenged since 2001 when the World Health Organization (WHO) has included in the domain of PMF a new category of patients, namely early/prefibrotic MF, characterized by the absence of relevant reticulin fibrosis in BM, dual megakaryocyte and granulocyte proliferation, and megakaryocyte dysplasia. This review is focused on summarizing the diagnostic uncertainties of early/ prefibrotic myelofibrosis, recent advances in our understanding of the biology of the variant, and the accompanying translational implications.",
keywords = "Bone marrow biopsy, Early/prefibrotic myelofibrosis, Essential throbocythemia, Primary myelofibrosis",
author = "Giovanni Barosi",
year = "2014",
doi = "10.1016/j.beha.2014.07.004",
language = "English",
volume = "27",
pages = "129--140",
journal = "Best Practice and Research in Clinical Haematology",
issn = "1521-6926",
publisher = "Bailliere Tindall Ltd",
number = "2",

}

TY - JOUR

T1 - Essential thrombocythemia vs. early/prefibrotic myelofibrosis

T2 - Why does it matter

AU - Barosi, Giovanni

PY - 2014

Y1 - 2014

N2 - Essential thrombocythemia (ET) and primary myelofibrosis (PMF), together with polycythemia vera (PV) are Phildelphia-negative (Ph-neg) classical myeloproliferative neoplasms (MPN). ET has been traditionally identified by thrombocytosis and absence of relevant bone marrow (BM) fibrosis, while PMF by BM reticulin or collagen fibrosis with megakaryocyte hyperplasia and dysplasia, and extramedullary hematopoiesis. These diagnostic profiles have been challenged since 2001 when the World Health Organization (WHO) has included in the domain of PMF a new category of patients, namely early/prefibrotic MF, characterized by the absence of relevant reticulin fibrosis in BM, dual megakaryocyte and granulocyte proliferation, and megakaryocyte dysplasia. This review is focused on summarizing the diagnostic uncertainties of early/ prefibrotic myelofibrosis, recent advances in our understanding of the biology of the variant, and the accompanying translational implications.

AB - Essential thrombocythemia (ET) and primary myelofibrosis (PMF), together with polycythemia vera (PV) are Phildelphia-negative (Ph-neg) classical myeloproliferative neoplasms (MPN). ET has been traditionally identified by thrombocytosis and absence of relevant bone marrow (BM) fibrosis, while PMF by BM reticulin or collagen fibrosis with megakaryocyte hyperplasia and dysplasia, and extramedullary hematopoiesis. These diagnostic profiles have been challenged since 2001 when the World Health Organization (WHO) has included in the domain of PMF a new category of patients, namely early/prefibrotic MF, characterized by the absence of relevant reticulin fibrosis in BM, dual megakaryocyte and granulocyte proliferation, and megakaryocyte dysplasia. This review is focused on summarizing the diagnostic uncertainties of early/ prefibrotic myelofibrosis, recent advances in our understanding of the biology of the variant, and the accompanying translational implications.

KW - Bone marrow biopsy

KW - Early/prefibrotic myelofibrosis

KW - Essential throbocythemia

KW - Primary myelofibrosis

UR - http://www.scopus.com/inward/record.url?scp=84925408151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925408151&partnerID=8YFLogxK

U2 - 10.1016/j.beha.2014.07.004

DO - 10.1016/j.beha.2014.07.004

M3 - Article

C2 - 25189724

AN - SCOPUS:84925408151

VL - 27

SP - 129

EP - 140

JO - Best Practice and Research in Clinical Haematology

JF - Best Practice and Research in Clinical Haematology

SN - 1521-6926

IS - 2

ER -